Details for New Drug Application (NDA): 022067
✉ Email this page to a colleague
The generic ingredient in FLO-PRED is prednisolone acetate. There are eighty-eight drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the prednisolone acetate profile page.
Summary for 022067
Tradename: | FLO-PRED |
Applicant: | Taro |
Ingredient: | prednisolone acetate |
Patents: | 1 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | EQ 5MG BASE/5ML | ||||
Approval Date: | Jan 17, 2008 | TE: | RLD: | No | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Oct 11, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF ALLERGIC REACTIONS | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Oct 11, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF ASTHMA |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | EQ 15MG BASE/5ML | ||||
Approval Date: | Jan 17, 2008 | TE: | RLD: | No | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Oct 11, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF ALLERGIC REACTIONS |
Expired US Patents for NDA 022067
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-002 | Jan 17, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-002 | Jan 17, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-001 | Jan 17, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-001 | Jan 17, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription